ABK Biomedical, a leading medical device company, has recently announced that its Eye90 microspheres device has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation is a significant milestone for ABK Biomedical and highlights the potential of the Eye90 microspheres device to revolutionize the treatment of ocular diseases.
The Eye90 microspheres device is a novel medical technology designed to deliver targeted radiation therapy directly to the eye. It is specifically developed for the treatment of ocular melanoma, a rare form of eye cancer that affects the uvea, the middle layer of the eye. Ocular melanoma can be a life-threatening condition if left untreated or if it spreads to other parts of the body.
Traditionally, the treatment options for ocular melanoma have been limited and often involve invasive procedures such as enucleation (removal of the eye) or brachytherapy (implantation of radioactive seeds). These treatments can have significant side effects and may not always be effective in preventing the spread of the disease.
The Eye90 microspheres device offers a non-invasive and targeted approach to treating ocular melanoma. It consists of tiny biocompatible microspheres that are loaded with a radioactive isotope called Yttrium-90. These microspheres are injected directly into the blood vessels that supply the tumor, allowing for precise delivery of radiation therapy to the cancerous cells.
The Breakthrough Device Designation from the FDA recognizes the potential of the Eye90 microspheres device to provide a significant improvement over existing treatment options for ocular melanoma. This designation is granted to medical devices that have the potential to address unmet medical needs and provide more effective treatment options for life-threatening or irreversibly debilitating diseases.
With this designation, ABK Biomedical will receive expedited review and priority access to FDA resources, including guidance and support throughout the development and regulatory process. This will accelerate the availability of the Eye90 microspheres device to patients who urgently need it.
The Eye90 microspheres device has already shown promising results in early clinical trials. A study published in the journal Ophthalmology reported that the device achieved tumor control in 92% of patients with ocular melanoma, with minimal side effects. These results indicate the potential of the Eye90 microspheres device to become a game-changer in the treatment of this rare and challenging disease.
In addition to ocular melanoma, ABK Biomedical is also exploring the potential applications of the Eye90 microspheres device in other ocular diseases, such as retinoblastoma (a childhood eye cancer) and age-related macular degeneration (AMD). These conditions affect millions of people worldwide and could benefit from the targeted radiation therapy offered by the Eye90 microspheres device.
The Breakthrough Device Designation from the FDA is a significant validation of ABK Biomedical’s innovative approach to treating ocular diseases. It highlights the potential of the Eye90 microspheres device to improve patient outcomes and revolutionize the field of ophthalmology. As ABK Biomedical continues to advance the development of this groundbreaking technology, patients and healthcare professionals can look forward to a new era in the treatment of ocular diseases.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: Plato Data Intelligence.
- Source Link: https://platohealth.ai/abk-biomedical-announces-that-its-eye90-microspheres-device-has-been-granted-breakthrough-device-designation-by-the-u-s-food-and-drug-administration-fda-biospace/
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States The Food and...